Improving Radiotherapy Plan Quality for Nasopharyngeal Carcinoma With Enhanced UNet Dose Prediction

IF 2.9 2区医学 Q2 ONCOLOGY Cancer Medicine Pub Date : 2025-02-15 DOI:10.1002/cam4.70688

Junming Jian, Xingxing Yuan, Longfei Xu, Changfei Gong, Xiaochang Gong, Yun Zhang

{"title":"Improving Radiotherapy Plan Quality for Nasopharyngeal Carcinoma With Enhanced UNet Dose Prediction","authors":"Junming Jian, Xingxing Yuan, Longfei Xu, Changfei Gong, Xiaochang Gong, Yun Zhang","doi":"10.1002/cam4.70688","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Individualized dose prediction is critical for optimizing radiation treatment planning. This study introduces <i>DESIRE</i>, an enhanced UNet-based dose prediction model with progrEssive feature fuSion and dIfficult Region lEarning, tailored for nasopharyngeal carcinoma (NPC) patients receiving volumetric modulated arc therapy. We aimed to assess the impact of integrating <i>DESIRE</i> into the treatment planning process to improve plan quality.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study included 131 NPC patients diagnosed at Jiangxi Cancer Hospital between 2017 and 2020. Twenty patients were randomly allocated to a testing cohort, while the remaining 111 comprised a training cohort. Target delineation included three planning target volumes (PTVs): PTV70, PTV60, and PTV55, along with several organs at risk (OARs). The <i>DESIRE</i> model predicted dose distributions, and discrepancies between <i>DESIRE</i>'s predictions and the ground truth (GT) were quantified using dosimetric metrics and gamma pass rates. Two junior physicians used <i>DESIRE</i>'s predictions for treatment planning, and their plans were compared to the GT.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Most of <i>DESIRE</i>'s predicted dosimetric metrics closely aligned with GT (mean difference < 1 Gy), with no significant differences (<i>p</i> > 0.05) in <i>D</i><sub><i>mean</i></sub> and <i>D</i><sub><i>1</i></sub> values across OARs. While significant differences were observed in PTV metrics, the mean differences in <i>D</i><sub><i>98</i></sub>, <i>D</i><sub><i>95</i></sub>, <i>D</i><sub><i>50</i></sub>, and <i>D</i><sub><i>mean</i></sub> between <i>DESIRE</i> and GT did not exceed 1 Gy. Assisted by <i>DESIRE</i>, the junior physicians' plans were comparable to the GT in nearly all OARs, with no significant differences in dosimetric metrics. The conformity index (CI) and homogeneity index (HI) for PTV70 surpassed the GT (0.847 ± 0.036 vs. 0.827 ± 0.037 for CI, and 0.057 ± 0.009 vs. 0.052 ± 0.008 for HI). The average three-dimensional gamma passing rates were 0.85 for PTV70 and 0.87 for the 35-Gy isodose line.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The <i>DESIRE</i> model shows promise for patient-specific dose prediction, enhancing junior physicians' treatment planning capabilities and improving plan quality.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 4","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70688","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70688","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Individualized dose prediction is critical for optimizing radiation treatment planning. This study introduces DESIRE, an enhanced UNet-based dose prediction model with progrEssive feature fuSion and dIfficult Region lEarning, tailored for nasopharyngeal carcinoma (NPC) patients receiving volumetric modulated arc therapy. We aimed to assess the impact of integrating DESIRE into the treatment planning process to improve plan quality.

Methods

This retrospective study included 131 NPC patients diagnosed at Jiangxi Cancer Hospital between 2017 and 2020. Twenty patients were randomly allocated to a testing cohort, while the remaining 111 comprised a training cohort. Target delineation included three planning target volumes (PTVs): PTV70, PTV60, and PTV55, along with several organs at risk (OARs). The DESIRE model predicted dose distributions, and discrepancies between DESIRE's predictions and the ground truth (GT) were quantified using dosimetric metrics and gamma pass rates. Two junior physicians used DESIRE's predictions for treatment planning, and their plans were compared to the GT.

Results

Most of DESIRE's predicted dosimetric metrics closely aligned with GT (mean difference < 1 Gy), with no significant differences (p > 0.05) in D_mean and D₁ values across OARs. While significant differences were observed in PTV metrics, the mean differences in D₉₈, D₉₅, D₅₀, and D_mean between DESIRE and GT did not exceed 1 Gy. Assisted by DESIRE, the junior physicians' plans were comparable to the GT in nearly all OARs, with no significant differences in dosimetric metrics. The conformity index (CI) and homogeneity index (HI) for PTV70 surpassed the GT (0.847 ± 0.036 vs. 0.827 ± 0.037 for CI, and 0.057 ± 0.009 vs. 0.052 ± 0.008 for HI). The average three-dimensional gamma passing rates were 0.85 for PTV70 and 0.87 for the 35-Gy isodose line.

Conclusions

The DESIRE model shows promise for patient-specific dose prediction, enhancing junior physicians' treatment planning capabilities and improving plan quality.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.